A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Christophe Corpechot(Inserm), Raoul Poupon(Inserm), Christine Silvain(Inserm), Alexandra Heurgué–Berlot(Inserm), Guillaume Lefèvre(Université de Lille), Maryline Debette‐Gratien(Inserm), G. Nkontchou(Inserm), Sara Lemoinne(Inserm), Dominique Larrey, Sylvie Chollet‐Martin(Unknown), Armand Abergel(Inserm), Victor de Lédinghen(Hôpital Cardiologique du Haut-Lévêque), Antonia Le Gruyer(Inserm), Isabelle Ollivier‐Hourmand(Inserm), Olivier Chazouillères(Inserm), Farid-Hakeem Admane(Université Paris-Sud), Fabien Zoulim(Hôpital de la Croix-Rousse), Jérôme Boursier(Michael E. DeBakey VA Medical Center), Éric Nguyen-Khac(Université de Lille), Dominique Rainteau(Inserm), Tabassome Simon(Sorbonne Université), Alexandra Rousseau(Houston Methodist), Luc de Chaisemartin(Inserm), Farid Gaouar(Inserm), Philippe Mathurin(Centre Hospitalier Universitaire de Lille), Odile Goria(Inserm), Jean‐Pierre Zarski(Inserm), Anne Minello(Inserm), Lydie Humbert(Inserm), François Habersetzer(Inserm), Pascal Potier(Inserm), Jean–Pierre Bronowicki(Inserm), Olivier Roux(Inserm)
Cited by 605
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789